Walter Jackson Stark

US Patent:

52618226, Nov 16, 1993

Filed:

Jan 12, 1993

Appl. No.:

8/003521

Inventors:

Deborah K. Hall - Menlo Park CA
Erik Rencs - Baltimore MD
Walter J. Stark - Baltimore MD

Assignee:

Iatrotech, Inc. - Del Mar CA

International Classification:

G09B 2328

US Classification:

434271

Abstract:

A phantom cornea for calibrating surgical lasers is formed by superimposition of thin-films of alternating colors. After ablation by a laser beam, the resulting spherical cavity appears as a pattern of nested circles whose concentricity and spacing reflect the alignment and intensity of the laser beam. These patterns can be visually or instrumentally analyzed to determine the proper setting of the laser. The calibration cornea can be planar, or arcuate to mimic the natural cornea. The calibration cornea may be mounted in a phantom eyeball including a removable iris of small diameter which constitutes a convenient target for the alignment of the laser beam.

US Patent:

20190275001, Sep 12, 2019

Filed:

Mar 18, 2019

Appl. No.:

16/357195

Inventors:

- Baltimore MD, US
Justin Hanes - Baltimore MD, US
Joshua Kays - Allston MA, US
Yun Yu - Nottingham MD, US
Ming Yang - Towson MD, US
Jeffrey Cleland - Baltimore MD, US
Walter Stark - Longboat Key FL, US
Qingguo Xu - Baltimore MD, US
Jin Yang - Shanghai, CN

International Classification:

A61K 31/404
A61K 31/506
A61K 9/51
A61K 9/00
A61K 9/19
A61K 9/16

Abstract:

Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or its analog or a pharmaceutically acceptable salt thereof. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or prevent a disease or disorder in or on the eye of a patient associated with vascularization, such as corneal neovascularization and acute macular degeneration. Upon administration, the sunitinib or its analog or salt is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity.

US Patent:

20170273901, Sep 28, 2017

Filed:

Dec 15, 2015

Appl. No.:

15/032986

Inventors:

- Baltimore MD, US
Justin Hanes - Baltimore MD, US
Joshua Kays - Baltimore MD, US
Yun Yu - Baltimore MD, US
Ming Yang - Towson MD, US
Jeffrey Cleland - San Carlos CA, US
Walter Stark - Baltimore MD, US
Qingguo Xu - Baltimore MD, US
Jin Yang - Shanghai, CN

International Classification:

A61K 9/00
A61K 9/16
A61K 31/404

Abstract:

Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or its analog or a pharmaceutically acceptable salt thereof. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or prevent a disease or disorder in or on the eye of a patient associated with vascularization, such as corneal neovascularization and acute macular degeneration. Upon administration, the sunitinib or its analog or salt is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity.

US Patent:

20170157147, Jun 8, 2017

Filed:

Aug 3, 2015

Appl. No.:

15/502732

Inventors:

- Baltimore MD, US
Qing Pan - Hangzhou, CN
Qingguo Xu - Baltimore MD, US
Nicholas J. Boylan - East Boston MD, US
Walter J. Stark - Baltimore MD, US
Bing Wang - Fujian Province, CN
Lixia Luo - Guangdong Province, CN

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 31/573
A61K 9/50
A61K 9/00
A61K 9/51

Abstract:

Particles encapsulating a glucocorticoid such as dexamethasone sodium phosphate (DSP) into a matrix such as biodegradable poly(lactic-coglycolic acid) (PLGA) which is densely coated with hydrophilic polymer such as PEG or PLURONIC F127, exhibit sustained release of DSP for up to 7 days in vitro. These nanoparticles can be used to prevent corneal graft rejection or corneal neovascularization.